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Abstract
Meticulous control of blood pressure is required in patients with hypertension to produce the maximum reduction in 
clinical cardiovascular end points, especially in patients with comorbidities like diabetes mellitus where more 
aggressive blood pressure lowering might be beneficial. Recent clinical trials suggest that the approach of using 
monotherapy for the control of hypertension is not likely to be successful in most patients. Combination therapy may 
be theoretically favored by the fact that multiple factors contribute to hypertension, and achieving control of blood 
pressure with single agent acting through one particular mechanism may not be possible. Regimens can either be 
fixed dose combinations or drugs added sequentially one after other. Combining the drugs makes them available in a 
convenient dosing format, lower the dose of individual component, thus, reducing the side effects and improving 
compliance. Classes of antihypertensive agents which have been commonly used are angiotensin receptor blockers, 
thiazide diuretics, beta and alpha blockers, calcium antagonists and angiotensin-converting enzyme inhibitors. 
Thiazide diuretics and calcium channel blockers are effective, as well as combinations that include renin-angiotensin-
aldosterone system blockers, in reducing BP. The majority of currently available fixed-dose combinations are diuretic-
based. Combinations may be individualized according to the presence of comorbidities like diabetes mellitus, chronic 
renal failure, heart failure, thyroid disorders and for special population groups like elderly and pregnant females.
Review
Achieving recommended goal of blood pressure (BP) {<
140/90 mmHg in all hypertensives, < 130/80 mm Hg in
hypertensives with diabetes mellitus (DM) [1]} is difficult
in majority of patients with hypertension [2]. Various
studies have shown that tight control of BP is required to
produce the maximum reduction in clinical cardiovascu-
lar end points [3,4]. The Framingham Heart Study[5]
indicated that a 2-mm Hg reduction in average diastolic
blood pressure (DBP) could result in a 14% decrease in
the risk of stroke and transient ischemic attacks and a 6%
reduction in the risk of coronary artery disease. A meta-
analysis of 9 major prospective observational studies also
showed that prolonged reduction in DBP of 5, 7.5, and 10
mm Hg were associated with 34%, 46%, and 56% fewer
strokes and 21%, 29%, and 37% lower incidences of coro-
nary heart disease respectively [6]. These data suggest
that more aggressive BP lowering might be beneficial.
Though single drug treatment may be effective in some,
more than 50% will require more than one drug for
appropriate control of their BP.
The Seventh Report of the Joint National Committee
on Prevention, Detection, Evaluation, and Treatment of
High Blood Pressure (JNC 7) and European Society of
Hypertension (ESH) guidelines recommend that therapy
with more than one antihypertensive agent be considered
in patients with systolic blood pressure (SBP) more than
20 mm Hg or DBP more than 10 mm Hg above goal and
among patients at high cardiovascular risk, as determined
by elevated BP level and the presence of other risk factors
[7,8]. The approach of combination therapy may be theo-
retically favored by the fact that multiple factors contrib-
ute to the hypertension and achieving control of BP with
single agent that acts through one particular mechanism
may be unrealistic. Combining the second agent may lead
to better control, acting by complimentary mechanism.
This review focuses the need and basis of combination
therapy, different classes of combination agents available
at present, rationale for their combination, comparisons
of these combinations and their effect on the outcome.
Basis of combination therapy
National Harris interactive survey for hypertension, in
the United States revealed that out of 90% patients taking
medication only 50% to 60% were involved in some form
of lifestyle change to control BP [9]. Thus majority of
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Page 2 of 11patients with hypertension rely on medication for the
control of their BP. More recent clinical trials suggest that
the approach of using monotherapy for the control of
hypertension is not likely to be successful in most
patients and specially in those with some comorbidities
(eg. DM, heart failure). The achievement of BP goal typi-
cally require 2 or more medications in various settings
[10-14]. For instance, [15] in a factorial study with 1461
patients randomized to 16 treatment groups, taking telm-
isartan 0, 20, 40, 80 mg and amlodipine 0, 2.5, 5, 10 mg for
8 weeks, greater BP reductions were observed with com-
bination therapy than with respective monotherapies.
Highest dose combination (telmisartan 80 mg plus amlo-
dipine 10 mg) had the greatest least square mean systolic/
diastolic BP reductions (26.4/20.1 mm Hg; P < 0.05 com-
pared with both monotherapies) with over 90% BP
response rates. Peripheral edema was most common in
the amlodipine 10-mg group (17.8%) but the rate had
notably lowered when amlodipine was used in combina-
tion with telmisartan. Similar results were observed with
other trial of olmesartan medoxomil/amlodipine combi-
nation therapy vs. respective monotherapies where more
effective BP reduction and BP goals (44.5-54% vs 28.5-
30%) were achieved with combination therapy than with
either of monotherapies. Over 70% of patients on combi-
nation therapy achieved BP goals [16].
Another double blind, parallel group randomized study
for 12 weeks comparing the combination therapy of felo-
dipine and metoprolol (5/50mg) with either monotherapy
exhibited significantly greater antihypertensive response
(98%) with combination compared to monotherapy (felo-
dipine- 79% and metoprolol- 82%). A significant greater
reduction in mean systolic/diastolic BP (28/18 mmHg)
with combination therapy was evinced compared to
either felodipine (18/12 mm hg) or metoprolol (19/12
mm hg) [17].
The long-term (I year) efficacy and safety between
lisinopril and trichlormethazide combination therapy and
lisinopril monotherapy was investigated in a multi-centre
open label trial on 466 patients. It showed effective BP
reduction to < 150/90 mmHg in both the groups through-
out the study period. Additionally the combination of
trichlormethazide reversed the increase in serum potas-
sium observed in the monotherapy group [18].
The results of these studies emphasize that multiple-
drug therapy was both safe and effective compared to
monotherapy and will be required in most patients to
attain BP goals.
Many panels including Hypertension in African Ameri-
cans Working Group (HAAWG), JNC 7, The Task Force
for the Management of arterial Hypertension of the ESH
and of the European Society of Cardiology have strongly
supported that treatment initiation with 2 or if needed 3
drugs is justified in many cases of hypertension manage-
ment [7-14,19]. There are other various advantages with
combination therapy. Combining the drugs makes them
available in a convenient dosing format, lowers the dose
and can be given in once daily schedule thus improving
compliance. There is an additive or synergistic antihyper-
tensive effect at lower doses of individual components
and at the same time the drugs in combination counteract
the side effects of each other. This helps more patients to
achieve normal BP and even can be effective in hard-to-
treat populations. Early normalization of BP may greatly
motivate the patients to adhere to lifelong treatment.
Available options in combination therapy
Multi-drug therapy regimens can either be fixed dose
combinations (FDCs) or drugs added sequentially one
after other. However, choice of combination antihyper-
tensive therapy will depend upon the tolerability and a
convenience of dosing/titrating drug regimen. FDCs can
enhance adherence to medication regimens compared
with treatment given as 2 separate agents. Also they facil-
itate more prompt reduction in BP. The use of antihyper-
tensive combinations started in the 1960s with
hydrochlorothiazide (HCTZ) combined with triam-
terene, a potassium-sparing diuretic, and has been added
with newer and different combinations in due course of
time [20].
Available trials have studied different classes of drugs in
combination for treatment of hypertension, taking
advantage of their complimentary action. Angiotensin
receptor blockers (ARBs), thiazide diuretics, alpha and
beta blockers, calcium antagonists(CCBs) and angio-
tensin-converting enzyme inhibitors (ACEIs) have been
the commonly used classes of antihypertensive agents.
Thiazide diuretics and CCBs are effective, as well as com-
binations that include rennin-angiotensin-aldosterone
system (RAAS) blockers, in reducing BP. Several combi-
nations of an ACEI or ARB with a diuretic or an ACEI
with a CCB are available. The majority of currently avail-
able FDCs are diuretic-based. Though diuretics have an
unparalleled track record of safety and efficacy, recent
data documenting low-grade carcinogenicity must be
evaluated further [21].
Some of the commonly available combinations are
listed in Table 1
Some of the combinations which have been studied in
detail are discussed below. Refer Table 2 for commonly
available FDCs.
β Blockers with diuretics
β-blockers and diuretics have been used for the treatment
of hypertension for more than three decades. Although
β-blockers did have a beneficial effect on the BP, β-
blocker therapy failed to favourably affect the cardiovas-
cular events and mortality either alone or in combination
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placebo- controlled studies, 10 active-controlled studies
and 11 meta-analyses for assessing the effects of β-block-
ers on cardiovascular and cerebrovascular outcomes in
the treatment of hypertension. Most of the studies
included atenolol and the combination drug often used
was thiazide diuretic. β-blockers showed increased risk
for stroke, cardiovascular events and mortality in major-
ity of the studies as compared to other anti-hyperten-
sives. Only 2 comparison studies of β-blockers evidenced
significant cardiovascular benefit [23].
Earlier it was a widely held belief that beta-blockers
should be prescribed for management of hypertension in
patients with higher heart rates, an established risk factor
for cardiovascular events. But recent Anglo-Scandinavian
Cardiac Outcomes Trial-Blood Pressure Lowering Arm
(ASCOT-BPLA) trial concluded that, in similar hyperten-
sive populations without previous or current coronary
artery disease, higher baseline heart rate is not an indica-
tion for preferential use of β-blocker-based therapy over
amlodipine based therapy. ASCOT BP-lowering arm
showed outcome inferiority of therapy initiated with
atenolol versus that initiated with CCB, amlodipine
(including mortality disadvantage) [24]. Also the risk of
sudden cardiac death was found to be higher in elderly
patients receiving either b-blockers as monotherapy, or in
combination with a thiazide diuretic, than in patients
receiving another form of therapy (CCBs, , or potassium-
sparing diuretics) [25].
So based on above evidence beta-blockers alone or in
combination should now have more restricted place in
cardiovascular therapy and can be possibly indicated in
hypertensives with anxiety and fast heart rate.
ACEIs/ARBs with Diuretics
RAAS inhibitor and a diuretic combination will offset the
diuretic-induced increase in plasma renin activity. The
salt loss will add to the antihypertensive effect of RAAS
blocker. Besides, an ARB will also attenuate the metabolic
effects of thiazide diuretics like hypokalemia and hyperg-
lycemia. Several studies have demonstrated the antihy-
pertensive effectiveness of this combination in low doses,
showing substantially greater reductions in BP and higher
response rates than either of the treatments alone [26,27].
The Action in Diabetes and Vascular Disease: Preterax
and Diamicron MR Controlled Evaluation (ADVANCE),
trial compared the effects of BP lowering with a perindo-
Table 1: Pharmacological rationale of combination therapy
Combinations Mechanisms
ARB-Diuretic ARBs cause the antagonism of angiotensin II at the 
vascular and myocardial level by direct AT-1 receptor 
blockade
Thiazide diuretic blocks sodium chloride 
reabsorption at the distal convoluted tubule
β-Adrenoceptor Antagonist-Diuretic The β-adrenoceptor blocker inhibits activation by 
direct suppression of renin release, inhibit β-
adrenergic sympathetic stimulation decreasing 
myocardial contractility and heart rate
Diuretics as above
ACEI-Diuretic ACEI cause the removal of the angiotensin II effect 
(vasoconstriction, stimulation of aldosterone 
secretion) and enhancement of kinin-mediated 
vasodilation
Diuretics as above
ACEI-CCB ACEI as above The calcium antagonists de-crease vascular 
resistance by vascular smooth muscle 
relaxation
ARB-CCB ARBs as above CCBs as Above
ACE-ARB Inhibitors ACEI as above ARBs as above
Centrally Acting Agents-Diuretic Clonidine acts by decreasing sympathetic outflow by 
stimulating pre synaptic α2-adrenoceptors in the 
vasomotor centre of the CNS.
Diuretics as above
Angiotensin Converting Enzyme (ACE) inhibitors, Angiotensin II type 1 Receptor Blockers (ARBs), Calcium Channel Antagonist (CCB)
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type 2 diabetic subjects. The risk of combined primary
outcome, a major macrovascular or microvascular event
was reduced by 9% (p = 0.041) with a 14% (p = 0.025)
reduction in all-cause mortality and an 18% (p = 0.027)
reduction in cardiovascular mortality. The study extrapo-
lated saving one death over 5 years for every 79 patients
with this ACEI/Diuretic combination [28]. Similarly clini-
cal studies have shown combination of the ARB, irbesar-
tan with HCTZ to be safe and effective in patients with
moderate to severe hypertension, irrespective of baseline
BP level, age, obesity, race, diabetic status, and the meta-
bolic syndrome and has a significantly greater dose-
dependent BP lowering effect than either agent alone
[29,30]. One study suggested that although a goal BP of <
140/90 mm Hg can be reached in the majority of patients
with SBP < 160 mm Hg with irbesartan monotherapy,
most patients with moderate to severe (stage 27 or grade
2 or 3) hypertension (baseline SBP ≥ 160 mm Hg) require
combination therapy for BP goal to be reached [31,32].
A trial with patients having uncontrolled BP despite
antihypertensive agents including an ARB (candesartan 8
mg/day or valsartan 80 mg/day) randomly assigned to
combination therapy with telmisartan 40 mg/day and
HCTZ 12.5 mg/day (T + H, n = 32) or to no change in
their current drug regimen (n = 32). Both office and
home BP was significantly reduced in T+H arm in 12
weeks. Also early morning BP was decreased inferring
the long duration activity of combination [33]. ONEAST
study also showed significant BP reduction in telmisar-
tan+amlodipine group than amlodipine group alone
(decrease in BP: -9.9+/-11.4 vs. -3.7+/-8.9 mm Hg, P <
0.02; normalization rate: 67.6 vs. 30.3%, P < 0.01). Thus it
seems that the combination of a RAAS blocker and a low-
dose thiazide is useful if treatment with a CCB cannot
control BP in patients with hypertension [34]. The results
of these studies confirm that diuretic/ACEI or diuretic/
ARB combinations reduce BP further than monothera-
pies in hypertensive diabetic subjects with an acceptable
safety profile.
RAAS Blocker with CCB
RAAS blocker buffer CCB-induced activation of the sym-
pathetic nervous system and the RAAS. Also the negative
sodium balance caused by CCBs adds to the antihyper-
tensive effect of RAAS blocker. Dose-dependent CCB
induced peripheral edema may be minimized in the pres-
ence of an RAAS blocker [35].
ACEIs with CCB
In patients with both diabetes and hypertension, ACEIs
provide clinical benefits that appear to be independent of
BP reduction [36]. In the Fosinopril vs Amlodipine Car-
diovascular Events Trial (FACET) [37] in patients with
hypertension and diabetes those receiving fosinopril were
approximately 50% less likely to experience a major car-
diovascular event than those receiving amlodipine when
followed for up to 3.5 years. The number of observed vas-
cular events was even lower in those who received combi-
nation. Similarly in Effects of Antihypertensive Agents on
Cardiovascular Events in Patients With Coronary Disease
and Normal Blood Pressure (CAMELOT) [38] 2 years of
treatment with amlodipine significantly reduced the inci-
dence of CV adverse events. The ANDI study demon-
strated that in hypertensive patients with diabetes whose
BP was not controlled with 20 mg quinapril alone, initia-
tion of combination therapy by adding 5 mg amlodipine
besylate to quinapril 20 mg was more effective in reducing
BP than increasing the dose of quinapril to 40 mg [39].
Table 2: Fixed- dose combinations with examples

























Angiotensin Converting Enzyme (ACE) inhibitors, Angiotensin II 
type 1 Receptor Blockers (ARBs), Calcium Channel Antagonist 
(CCB), hydrochlorothiazide (HCTZ), renin- angiotensin-
aldosterone system (RAAS)
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The rationale for combination therapy with agents that
block the RAAS and a CCB or diuretic is well founded
[40]. However, the use of ARBs and CCBs has indepen-
dent benefits beyond BP lowering, on morbidity and
mortality in patients with hypertension and comorbid
conditions. In the Losartan Intervention for Endpoint
Reduction in Hypertension (LIFE) study, a losartan-based
(ARB) regimen significantly reduced the relative risk of
cardiovascular-related morbidity and death in hyperten-
sive patients with left ventricular hypertrophy by 13% (P
= .02). The reduction came, however, mostly as a result of
a 25% reduction in the relative risk of stroke (P = .001),
compared with atenolol-based therapy, yet the between-
group difference in SBP was only 1 mm Hg [41]. More-
over telmisartan has a different pharmacokinetic profile
compared to other ARBs, and there are few studies exam-
ining telmisartan/CCB combinations in hypertensive
patients [42,15].
In Fogari et al. [42] study, 40 mg of telmisartan and 2.5
mg of amlodipine combination was used. After 4 weeks
patients whose BP was not controlled (BP > 130/80 mm
Hg) were randomized to two-dose titration regimens, one
based on increasing doses of telmisartan (up to 160 mg
daily) and fixed 2.5-mg dose of amlodipine, the other
based on increasing doses of amlodipine (up to 10 mg
daily) and fixed 40-mg dose of telmisartan. It was found
that at comparable levels of BP reduction, urinary albu-
min excretion rate decreased more in subjects treated
with escalating doses of telmisartan. Overall, among the
different combinations of telmisartan and amlodipine, it
is clear that telmisartan 80 mg plus amlodipine 10 mg is
the most effective combination and the telmisartan and
amlodipine combinations offer a very effective and toler-
able option particularly in susceptible patients that
require combination therapy.
ACEIs with ARB
An ACEI/ARB regimen theoretically may provide the
advantage of a more complete blockade of the RAAS.
ARB will reduce the ACEI escape phenomenon, a mecha-
nism whereby angiotensin II returns to pretreatment lev-
els despite continuous ACEI treatment. Furthermore,
angiotensin II generated by ACEI-independent pathways
will get blocked by ARBs. Additionally the ACEI itself
inhibits bradykinin degradation [43].
Clinical studies of properly dosed ACEI and ARB com-
binations have demonstrated significant improvement
with regard to target organ damage, specifically heart fail-
ure and proteinuria. The first major study in this area was
the CALM (Candesartan and Lisinopril Microalbuminu-
ria) trial, which was designed to compare the effect of
candesartan 16 mg or lisinopril 20 mg or both on BP and
urinary albumin-creatinine ratio in 197 type 2 hyperten-
sive microalbuminuric diabetic patients. All three treat-
ments resulted in a significant decrease in both BP and
albuminuria. The combination treatment was signifi-
cantly more effective than monotherapy in reducing BP
and resulted in a greater decrease in albuminuria,
although this was statistically significant only when the
combination was compared with candesartan monother-
apy [44].
In the Combination Treatment of angiotensin II recep-
tor blocker and Angiotensin-Converting Enzyme inhibi-
tor in nondiabetic renal Disease (COOPERATE) trial,
[45,46] the incidence of a composite renal outcome was
reduced by about 60% with combination therapy relative
to both monotherapies. However, BP was not lowered to
a significantly greater degree than either therapy alone.
The Randomized Evaluation of strategies for left Ventric-
ular Dysfunction (RESOLVD) pilot study[47] on patients
with heart failure, receiving candesartan, enalapril, or the
combination therapy, showed combination therapy to
have a more beneficial effect on cardiac volumes and
ejection fraction.
However, the potential hazards of ARB plus ACEI com-
binations must also be taken into consideration: such
combinations often produce worsening of hyperkalemia,
[48] and may be associated with a decline in the hemat-
ocrit in chronic renal failure(CRF) patients with renal
anemia [49]. So, the patients receiving this combination
treatment should be carefully monitored, particularly in
subjects with renal artery stenosis, those receiving con-
comitant cyclooxygenase inhibitors, or in the elderly, salt
depleted, or anemic.
Comparison of available combinations
Various randomized studies have been conducted to
compare fixed combinations of one class with fixed com-
binations of another class [50-58]. Combinations evalu-
ated are ACEIs/diuretics, ACEIs/CCBs (dihydropyridine
and non - dihydropyridine CCBs), β-Adrenoceptor
Antagonist/diuretics and ARB/diuretics.
ACEI/CCBs, ACEI/diuretics and β-adrenoceptor
antagonist/diuretics all are significantly effective than
placebo and helpful in achieving DBP < 90 mm Hg [50].
ACEI/CCBs combination is more effective at reducing
both SBP and DBP. ACEI/non dihydropyridine CCBs and
ACEI/diuretic have similar efficacy [45,46]. ACEI/dihy-
dropyridine CCBs (amlodipine, manidipine, nitrandip-
ine) combination is more efficacious than ACEI/diuretic
combination in reducing both SBP and DBP to a signifi-
cant extent[47,48]. β-adrenoceptor antagonist/diuretic is
similarly effective to ACEI/diuretic and ACEI/CCBs[52].
But β-adrenoceptor antagonist/diuretic have adverse
effect on serum lipids and glycemic parameters over one
year of treatment [54].
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maturely after 5.5 years of median follow-up because
there was significantly less risk of secondary end points,
including nonfatal myocardiac infarction(MI), total car-
diovascular end points, all-cause mortality, stroke, and
heart failure in patients treated with amlodipine/perindo-
pril compared with those treated with atenolol/bendrofl-
umethiazide. There was also a nonsignificant trend
toward reduced risk for the primary end point (nonfatal
and fatal MI) favoring amlodipine/perindopril treatment
[24]. A subsequent analysis, adjusting for mean BP level,
demonstrated reductions of 13% (P < .014) and 17% (P <
.018), respectively, in risks for the primary end point and
stroke [55].
In patients with metabolic syndrome, ACEI/CCBs are
preferred over β-adrenoceptor antagonist/diuretic and
ARB/diuretic combination. ARB/diuretic are associated
with marked changes in glucose parameters and a higher
incidence of new onset diabetes (26%) as compared to
ACEI/CCBs (11%) [56] In patients with Type 2 diabetes
although BP reduction is greater with β-adrenoceptor
antagonist/diuretic, glycemic control is better stable in
patients treated with ACEI/CCBs [57]. In non-diabetic
patient, β-adrenoceptor antagonist/diuretic is less effec-
tive in reducing DBP compared to ACEI/CCBs (but simi-
lar SBP reduction) and had less effect on pulse wave
velocity [58].
The ACCOMPLISH trial compared the ACEI
benazepril plus the diuretic hydrochlorothiazide (force-
titrated to 40/12.5 mg, with the option to raise to 40/25
mg) and benazepril plus amlodipine (force-titrated to 40/
5 mg, with the option to raise to 40/10 mg) on a compos-
ite cardiovascular mortality and morbidity end point [59].
This combination reduces metabolic disturbances such as
hypokalaemia, hyperuricaemia and hypercholesterolae-
mia, which are all frequent with diuretic monotherapy.
The study was terminated prematurely at 36 months
because the global cardio vascular disease (CVD) event
rate (myocardial infarction, stroke, coronary interven-
tion, heart failure, and other fatal or non fatal cardiovas-
cular disease) diverged early and linearly throughout the
trial and was about 19.6% lower (9.6% vs. 11.8%; p,0.001)
in those who received amlodipine/benazapril compared
to those who received hydrochlorothiazide/benazapril.
ARB/diuretic is similarly effective to ACEI/CCBs in
controlling 24 hours BP on ambulatory blood pressure
monitoring but less effective in achieving SBP < 140 mm
Hg and also associated with poorer metabolic control and
new onset diabetes as discussed above [60].
Some important special situations
Metabolic syndrome and Hypertension
A) Diabetes and Proteinuria Hypertension may act syn-
ergistically with diabetes in increasing the risk of both
macrovascular and microvascular comlplications of dia-
betes [61]. Various trials, some of which have been ran-
domized, have shown decrease in these complications
when BP was lowered to safer limits (< 130/80 mm of
Hg). This BP control has been found to be difficult to
achieve with monotherapy [62]. Indeed, although ACEIs,
ARBs, CCBs, diuretics, and β blockers all have compel-
ling indications in diabetes, it is suggested that combina-
tion therapy should include, as initial therapy, an agent
that interrupts the RAAS. Second drug can be CCBs or
diuretics, or ACEI plus an ARB combination.
The results have consistently shown a beneficial reno-
protective effect of ACEIs and ARBs in diabetic nephrop-
athy. The combined therapy with an ARB and a CCB has
a potentially useful antiproteinuric effect in patients with
type 2 diabetic nephropathy, even when their renal func-
tion is reduced. This was also shown in Fogari et al study
also [42]. Although treatment with an ARB plus an ACE-I
has a greater antiproteinuric effect, but it may be associ-
ated with complications including worsening of renal
anemia and increased serum potassium concentrations,
especially in patients whose kidney function is mildly to
moderately impaired.
B) Dyslipidemia and Hypertension Hypertension and
dyslipidemia are conditions that can coexist frequently.
National Health and Nutrition Examination Survey
(NHANES III) has shown that 64% of patients with
hypertension also have dyslipidemia and conversely,
approximately 47% of patients with dyslipidemia have
hypertension. Hypertension and hypercholesterolemia
are the two leading risk factors for heart disease, These
two together cause an increase in coronary heart disease
related events [63].
In addition to its anti-hypertensive effect through
antagonizing AT1 receptors, telmisartan has a unique
property that activates peroxisome proliferator-activated
receptor-γ (PPAR-γ) and is suggested to improve insulin
sensitivity and reduce triglyceride levels, leading to a
reduction of the risk for atherosclerosis. Miura et al. [64]
demonstrated that 12 weeks of treatment with telmisar-
tan (in exchange for valsartan or candesartan) resulted in
significant decreases in fasting insulin, fasting blood glu-
cose, hemoglobin A1c and triglycerides; and increases in
high density lipoprotein cholesterol and adiponectin,
suggesting a potential metabolic and anti-atherogenic
benefit.
Saga Telmisartan Aggressive Research (STAR) study
evaluated 197 patients being prescribed 20 to 80 mg of
telmisartan for 6 months. Total cholesterol (TC) levels
decreased from 200 to 188 mg/dl (p < 0.05). Triglyceride
levels were decreased 270 to 175 mg/dl (p < 0.005) in
patients with TG levels ≥ 150 mg/dl [65]. Telmisartan
may accelerate reverse cholesterol transport or inhibit net
cholesterol absorption through activation of ABC1, lead-
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[66]. These results suggest that telmisartan may have the
ability to lower cholesterol levels, further controlled stud-
ies will be needed to confirm these findings. Thus using a
telmisartan alone or in combination with a diuretic/CCB
can be efficacious in patients with dyslipidemia.
Heart failure with Hypertension
Treatment of hypertension in patients with heart failure
must take into account the type of heart failure, systolic
dysfunction or diastolic dysfunction, in which there is a
limitation to diastolic filling and therefore in forward out-
put due to increased ventricular stiffness. Diuretics, beta
blockers, ACEIs, ARBs, and aldosterone antagonists are
indicated in the management of heart failure and have
been shown to reduce morbidity and mortality in appro-
priately selected patients with heart failure. Hyper-
kalemia could be the side effect of some of these drugs so
the drugs like ACEIs, ARBs, and aldosterone antagonist
in combination should not be used. The choice of agents
is based on severity of heart failure, left ventricular ejec-
tion fraction, history of myocardial infarction and any
other associated comorbidities.
In these patients, treatment with ACEIs [67] and β-
blockers[68] has been shown to improve symptoms and
reduce the risk of death and hospitalization for worsening
heart failure. β blockers have now become the most
extensively studied class of agents in the treatment of
Chronic heart failure (CHF), with a database of over 6000
patients in placebo-controlled studies, and ongoing clini-
cal and mechanistic studies. Despite this, further ques-
tions remain regarding the use of these agents in CHF,
including their role in the extreme elderly, in patients
with DM. 2,289 patients with severe CHF in Carvedilol
Prospective Randomized Cumulative Survival (COPER-
NICUS) study, showed improved clinical status and
reduced the risk of death with carvedilol as compared to
placebo. However, because patients with the lowest SBP
were at highest risk of an event, they experienced the
greatest absolute benefit from treatment with carvedilol
[69].
Angiotensin II type 1 receptor blockers have favourable
effects on haemodynamic measurements, neurohumoral
activity, and left-ventricular remodelling when added to
in patients with ACEIs CHF. The primary outcome of the
CHARM- Added study was the composite of cardiovas-
cular death or hospital admission for CHF. Candesartan
reduced each of the components of the primary outcome
significantly, as well as the total number of hospital
admissions for CHF. The benefits of candesartan were
similar in all predefined subgroups, including patients
receiving baseline beta blocker treatment. The addition
of candesartan to ACEI and other treatment leads to a
further clinically important reduction in relevant cardio-
vascular events in patients with CHF and reduced left-
ventricular ejection fraction [70].
ONTARGET showed that the ARB telmisartan and the
ACEI ramipril are equally effective in preventing cardio-
vascular events in high-risk patients and that the combi-
nation provides no added benefit and causes more
adverse effects than either monotherapy in this patient
population. However, ONTARGET does not rule out use
of the ACEI plus ARB combination in severe heart failure,
where angiotensin escape mechanisms are expressed and
dual blockade may be needed [71].
Chronic renal failure with Hypertension
Hypertension can be caused by chronic kidney dis-
ease(CKD) but it itself can worsen the renal failure. The
guidelines state that management of hypertension in
CKD should focus on reducing BP, with some also
emphasizing reducing protein excretion.Choice of agent
will primarily depend on the presence of proteinuria as
there is a direct relationship between the degree of pro-
teinuria and progression to end stage renal disease. In
proteinuric kidney first line agents include an ACEIor
ARB, and often requires the addition of a diuretic or a
calcium channel blocker. Diuretics are a useful alternative
for non-proteinuric patients or as an add-on to renin-
angiotensin system blockade. Multiple drug therapy is
often needed to maintain BP below the 90th percentile
target, but adequate BP control is essential for better
renal and cardiovascular long-term outcomes. Thiazide
diuretics can be used if glomerular filtration rate (GFR) is
greater than or equal to 40 mL per minute per 1.73m2
(body surface area), and loop diuretics are used in GFR
less than or equal to 40 to 50 mL per minute per 1.73
m2[72] Various trials like AASK (African American Study
of Kidney Disease), IDNT (Irbesartan in Diabetic Neph-
ropathy Trail), RENAAL (Reduction of Endpoints in
Non-insulin dependent diabetes mellitus with the Angio-
tensin II Antagonist Losartan) show significant risk
reduction for CKD progression when proteinuria was
reduced by greater than 30% at 6 months.
Recently, combined therapy with an ACEI and an ARB
has been shown to provide a greater reduction in urinary
albumin excretion (UAE) than monotherapy with either
of these agents in patients with diabetic nephropathy.
However, such combinations may be associated with
potential hazards, including increased serum potassium
concentrations and worsening of renal anemia, especially
in patients whose kidney function is mildly to moderately
impaired [44-47].
Fogari et al. [42] evaluated the effect of a combination
therapy with the ARB telmisartan and the long-acting
CCB amlodipine on urinary albumin excretion
rate(UAER) in hypertensive patients with type 2 diabetes
and microalbuminuria. The results of this study demon-
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dipine combination was as effective as low-dose
telmisartan/high-dose amlodipine combination in reduc-
ing BP values during the 48-week study period without
affecting glycemic control or electrolyte plasma levels,
but the effect on UAER was significantly more pro-
nounced with the high-dose telmisartan combination,
despite equivalent BP-lowering effect [42].
Hypertension in thyroid disorders
The prevalence of hypertension among patients with
hypothyroidism is approximately 3%. Hypertension is
much more frequently associated with hyperthyroidism,
the prevalence is estimated at 20% to 30%. Hypothyroid
state has been shown to accelerate the age-related
increases inBP. Studies have shown a significant correla-
tions between DBP and either T4 or T3 suggesting that
thyroid hormone deficiency contributes to increase in BP
when it is slight to moderate. The mechanism of
increased BP in hypothyroidism is not known, but sug-
gested mechanism could be acceleration of structural
change of vascular tissue by thyroid hormone deficiency
and alteration of autonomic nervous function by thyroid
hormone deficiency leading to hemodynamic changes. In
patients of thyrotoxicosis, systolic pressures are typically
elevated and diastolic pressures are often low, which
results in a widened pulse pressure. These findings are
attributable to increased cardiac output, stroke volume,
heart rate, and cardiac contractility. Although many
symptoms of thyrotoxicosis can be controlled with beta-
adrenergic blockers, catecholamine levels are usually nor-
mal or even decreased. Despite the fact that the activity of
the RAAS is increased in patients with thyrotoxicosis,
ACEIs and angiotensin II receptor blockers do not always
reduceBP. Thus, the role of the RAAS in hypertension
associated with thyrotoxicosis remains to be defined.
Hypertension in elderly population
The estimated prevalence of hypertension in the United
States is 66% in men and women aged 60 years and older,
which is the highest among all age groups [73]. A
metaanalysis showed that treating hypertension in the
elderly yields the greatest benefits in relation to stroke
(odds ratio, 0.78) and coronary heart disease (odds ratio,
0.75). Importantly, total mortality and coronary heart dis-
ease mortality were found to be significantly reduced.69
Treating hypertension in older patients requires attention
to their altered physiology and to concomitant cardiovas-
cular and renal disease, which may indicate use of partic-
ular antihypertensive drugs. No specific guidelines exist
for hypertension management for this particular popula-
tion. However studies have shown requirement of two or
more drugs in most of them. Combination therapy is
often necessary to treat isolated systolic hypertension,
but control is only reached in 70% of patients in clinical
trials following an algorithm [74,75].
Till date, the most encouraging data supporting aggres-
sive management of hypertension in the elderly popula-
tion comes from the Hypertension In the Very Elderly
Trial (HYVET), a randomized, double-blind placebo trial
that enrolled 3,845 patients from 195 centers in Europe,
China, Australia, and North Africa. Patients were started
with indapamide/placebo and were added with perindo-
pril if BP of 150/80 mmHg was not achieved. Fatal stroke,
cardiovascular death, heart failure got reduced by 39%,
23% and 64% respectively in a median follow up of 1.8
years. Thus HYVET and other trials favor mono-therapy
or combination therapy with thiazide diuretics, ACEIs
and CCBs for hypertension in the elderly [76].
Hypertension in Pregnancy and Breast feeding
Hypertension complicates 5% to 7% of all pregnancies. A
subset of preeclampsia, characterized by new-onset
hypertension, proteinuria, and multisystem involvement,
is responsible for substantial maternal and fetal morbidity
and is a marker for future cardiac and metabolic disease
[77].
Drugs preferred during the pregnancy are
Ist line - Methyl dopa, Beta blocker (propranolol) and
Labetalol
IInd line - Metoprolol, atenolol and Calcium channel
blocker (nifedipine)
IIIrd line agents-clonidine, diuretics
Three short acting antihypertensive agents-hydrala-
zine, labetalol, and short acting (sublingual or orally
administered) nifedipine-are commonly used to control
acute, very high blood pressure in women with severe
hypertension in pregnancy.
Maternal antihypertensive drugs usually compatible
with breastfeeding are Captopril, diltiazem, Enalapril,
Hydralazine, Hydrochlorothiazide, Labetalol, Methyl-
dopa, Minoxidil, beta blockers like Propranolol and
timolol, spironolactone and verapamil. Individual side
effects of drugs have to be looked for, while prescribing
these drugs in lactation.
Combination of more than 2 drugs
Few patients may require a third or fourth drug to ade-
quately manage BP. Preference should be given to the
selection of an agent from a different class than the initial
2 drugs in the combination therapy. Addition of the third
drug may be in the form of spironolactone (requires the
assessment of renal functions and potassium), minoxidil,
hydralazine, carvedilol and rest of the drugs depending
on the specific conditions being treated. Centrally acting
drugs should be the last option due to potential side
effects.
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ACEIs- Pregnancy, angioneurotic edema, hyperkalemia,
renal artery stenosis
Diuretics- Gout, Hypokalemia, Pregnancy, Impaired
glucose tolerance,
Beta blockers- Asthma, marked bradycardia, abnormal
glucose tolerance, obstructive pulmonary disease,
peripheral artery disease
ARB- Pregnancy, hyperkalemia, renal artery stenosis
Ca channel blockers- Heart failure, bradyarrythmias
Concept of "Polypill"
It is generally accepted that reducing the pill burden
improves adherence and/or compliance to therapy,
though very few data is available to support this theory.
Wald and Law introduced the term "polypill" in 2003.
Polypill has been thought as a single daily pill to prevent
CVD by simultaneously reducing four risk factors (LDL
cholesterol, BP, platelet function, and serum homo-
cysteine). It usually is composed of a statin, three pres-
sure-lowering drugs, each at half of its standard dose,
aspirin, 75 mg, and folic acid. The polypill was suggested
to reduce ischemic heart disease by 88% and stroke by
80% if taken by everyone over 55 years of age [78].
However, our patients present with a puzzle of clinical
features, for which variable doses of the specific medica-
tion is required. The polypill provides fix combination of
substances, possibly resulting in undertreatment of the
main condition(s) and overtreatment of secondary condi-
tions. It also neglects differences in metabolism due to
age, race and sex. Even after some studies showing its
effectiveness the idea is still under investigation and
needs to be studied further [79].
Conclusion
Hypertension is now considered as a part of a complex
syndrome of changes in cardiac and vascular structure
and function. All of the current guidelines suggest that ≥
1 antihypertensive agent is required in most patients with
hypertension to reach BP goals that will effectively reduce
the cardiovascular risk. Therapy with 2 drugs separately
or with fixed combinations that include agents with com-
plementary actions. Many combinations have been
shown to improve cardiovascular outcome and include a
diuretic with the RAAS blocker. Choice of combination
therapy depends upon the risk factors, presence of
comorbidities like diabetes, renal dysfunction and the
adverse effects and tailored according to individual
patient.
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